Head-To-Head Comparison: China SXT Pharmaceuticals (NASDAQ:SXTC) vs. PMV Pharmaceuticals (NASDAQ:PMVP)

PMV Pharmaceuticals (NASDAQ:PMVP) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Institutional and Insider Ownership

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for PMV Pharmaceuticals and China SXT Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	2	1	2.75
China SXT Pharmaceuticals	1	0	0	0	1.00

PMV Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 222.58%. Given PMV Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe PMV Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Earnings & Valuation

This table compares PMV Pharmaceuticals and China SXT Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.83
China SXT Pharmaceuticals	$1.14 million	2.14	-$6.20 million	N/A	N/A

China SXT Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals.

Profitability

This table compares PMV Pharmaceuticals and China SXT Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
China SXT Pharmaceuticals	N/A	N/A	N/A

Risk and Volatility

PMV Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Summary

PMV Pharmaceuticals beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.